AUTHOR INDEX - Drug Metabolism and...
16
AUTHOR INDEX Abadla, A. R., 197 Abbott, Frank S., 1383 Abdallah, Claude, 584 Acheampong, Andrew A., 708 Adams, Delyth A., 929 Adams, Paula C., 982 Ader, Jean-Claude, 813 Agen, Cristiana, 713 Aigbirhio, Franklin I., 832 Albet, Carlos, 976 Ali, Syed F., 881 Anari, M. Reza, 536 Anders, M. W., 48, 124, 875 Anderson, Christopher D., 1286 Anderson, Kathleen, 799 Andersson, Paul, 137 Andrews, Paul A., 178 Anglada, Lluis, 976 Angus, P. W., 485 Appleton, Martin L., 595 Arison, Byron H., 266 Astrom, Anders, 137 Atta-Asafo-Adjei, E., 1431 Augustijns, Patrick F., 1372 Baba, Takahiko, 1195 Bader, Augustinus, 1315 Bai, Xigeng, 993 Bailey, G. S., 965 Baker, Max T., 60 Balani, Suresh K., 185, 266, 688 Baron, Jeffrey, 1346 Barton, H. A., 1202 Bazin-Redureau, M., 1400 Beauchamp, Lilia, 1242 Bellward, Gail D., 1407 Bend, John R., 577 Benet, Leslie Z., 369, 825, 900, 1099 Benfenati, E., 113 Benoit, Etienne, 160 Bergeron, Raymond J., I 1 17 Besner, Jean Guy, 584 Bhagwat, Shripad V., 651 Bhalla, Kapil N., 506 Bhargava, Ravi, 1110 Bijloo, G. J., 667 Binienda, Zbigniew, 881 Binkley, Shelly N., 1231 Birner, Gerhard, 861 Bischer, Alfred, 900, 1099 Bishop, Warren P., 299 Blake, P., 433 Blake, Timothy, 799 Blanz, Joachim, 94 Boado, Ruben J., 55, 1297 Bocci, Guido, 713 Bockbrader, Howard N., 441 Boehlert, C. C., 1225 Bonfils, Claude, 1253 Borchardt, Ronald T., 1372 Born, Stephanie L., 702 Bornheim, Lester M., 825 Boudinot, F. Douglas, 655, 1368 Bowers, Gary D., 724 Boyd, Michael R., 651 Bozler, Gerhard, 1206 Bracken, William, 736 Bradbury, Alan, 393 Brady, Alexandra N., 60 Brashear, Wayne T., 1202 Brendel, K., 497 Brendel, Klaus, 327 Brennan, Beverley, 349 Brewer, T. 0., 1, 18 Brien, James F., 1248 Bugelski, Peter J., 1044 Buhler, Donald R., 1263 Bull, Richard J., 1412 Bullock, Peter, 736 Burka, Leo T., 232 Burke, M. Danny, 1274 Burlingame, Alma L., 369 Burmaster, Steve D., 631 Buronfosse, Thierry, 160 Busch, Ulrich, 1206 Buters, Jeroen T. M., 696 Cannell, Richard J. P., 724 Carbonaro, Michael A., 1044 Carlson, Timothy J., 749 Carrel, Barb K., 757 Cashman, John R., 1143 Castagnoli, Neal, Jr., 749 Castell, Jos#{233} V., 553 Castillo, Marta, 566 Castle, Pamela J., 1037 Catlow, John, 916 Cerniglia, Carl E., 1417 Chakravarty, Prasun K., 207 Chang, I. Y., 529 Chang, Tsun, 441 Chapelle, P., 1400 Chauret, N., 65, 1325 Chay, Sylvia H., 916 Chen, Guangping, 1346, 1390 Chen, 1-Wu, 266, 730 Chen, Roger, 207 Chenery, Richard, 349 Chenery, Richard J., 251 Cheng, Lawrence K., 631, 806 Cheraghali, A. Majid, 223 Chesson, S. M., 951 Chiba, Masato, 622 Chikai, Toshiyuki, 35 Ching, Michael S., 190 Chiu, Shuet-Hing Lee, 207, 1126 Cho, Arthur K., 201, 610 Cho, Joon H., 840 Cho, Joo Youn, 460 Cho, Yong-Baik, 1280 Choudhuri, Supratim, 1291 Choudhury, Ruksana, 314 Chouini-Lalanne, Nadia, 813 Chow, Moses S. S., 449 Christians, Uwe, 1315 Chu, Chung K., 655 Chu, Teresa Y. Y., 201 Chung, Woon-Gye, 1263 Clank, B., 922 Clarke, Stephen E., 251 Coassolo, P., 1051 Coldham, N. G., 501 Collins, Michael A., 102 Colthup, P. V., 1225 Conroy, Robert, 904 Cooper, A. E., 922 Coutts, Ronald T., 525 Creveling, Cyrus R., 430 Cribb, Alastair, 671 Cribb, Alastair E., 406, 536 Crom, William R., 1110 Crooks, Peter A., 1175 Crowl, Robert, 904 Crowley, Jan R., 786 Cutler, N. Shame, 595 Dahl, A. R., 529 Danesi, Romano, 713 Dannecker, Robert, 321, 327 Dave, M., 501 Davies, Donald S., 929 Davies, Malonne I., 1072 Davis, Charles B., 1028, 1044 Dawson, Michael J., 724 Dean, Dennis C., 1126 de Bruijn, E. A., 433 De Francesco, L., 197 De Graeve, Jean, 1305 de Groot, M. J., 667 DeHart, Peter D., 441 Dekant, Wolfgang, 861 Delatour, Paul, 160 de Leon, Jesus H., 1354 del Tacca, Mario, 713 de Miranda, Paulo, 1242 Demuth, Sandra 0., 1028 De Sousa, G., 1051 De Sousa, Georges, 308 Dickinson, Ronald G., 119 Dimova, Hnistina, 1117 Ding, Andreas, 369 di Paolo, Antonello, 713 Distefano, Emma W., 201, 610 Divakaruni, Prasanna, 295 Dixon, C. M., 1225 Dolan, M. Eileen, 1394 Domergue, Jacques, 1253 Donato, M. Teresa, 553 Draile, Henning, 1315 Draper, Alison, 736 Dreyer, Geoffrey, 799 Dubd, D., 1325 Ducharme, Y., 65 Duescher, Renee J., 846 Duffel, Michael W., 1346 Duha.rt, Benjamin, Jr., 1417 Dulik, Deanne M., 1004 Du Souich, Patrick, 279, 584 Dwoskin, Linda P., 1175 Dwyer, Lynn M., 688 1436 Eddershaw, Peter J., 724 Edwards, Robert J., 929 Ehlhardt, William J., 910 Ehninger, Gerhard, 94 Ekins, Sean, 1274 Elder, Cheryl A., 776 Elfarra, Adnan A., 846 Ellis, Andrew G., 363 Ellis, Joan D., 688 Ellis, Martin K., 102 El Mansouri, S., 227 Endo, Takahiko, 1022 Escousse, Andr#{233},343 Estabrook, R. W., 765 Evans, Frederick E., 1417 Evans, William E., 1 1 10 Facchine, Kevin L., 869 Fagliano, Jerald A., 607 Faiman, Morris D., 1153 Falany, Charles N., 945 Fasanmade, Adedigbo A., 573 Fasco, Michael J., 1339 Fedorov, Ivan I., 655 Fenselau, Catherine, 119 Ferrero, J. L., 765 Ferrero, James L., 1143, 1163 Finkelstein, Martin B., 124 Finley, Brent, 607 Fischer, VoWer, 327 Fisher, M. B., 1431 Fisher, Robert A., 415 Fisher, Robyn L., 327 Fong, Kei-Lai, 799 Fortin, R., 1325 Foster, David J. R., 892 Foumel-Gigleux, Sylvie, 1305 Franklin, Michael R., 1379 Fredenbung, Andrea M., 1178 Freeman, James P., 1417 Freemantle, Christopher A. J., 832 Freund, Stefan, 94 Friesen, R., 1325 Fujii, Y., 28 Fujikawa, A., 28 Fujio, Nami, 999 Fujioka, M., 28 Fujisawa, Masae, 1022 Fujita, Shoichi, 1268, 1301 Fujitsu, T., 28 Fukuyama, Takako, 779 Funae, Yoshihiko, 610, 999 Furst, Sylvia M., 590 Galceran, M. Teresa, 976 Gandolfi, A. J.,497 Ganguly, Tanmoy C., 945 Gargas, Michael, 607 Garland, William A., 904 Garton, Kyle J., 1426 Garver, Eric, 799 Geerts, Rita J. F., 216 Gerstenberg, B., 143 Ghabrial, H., 485 Ghabrial, Hany, 190
Transcript of AUTHOR INDEX - Drug Metabolism and...
AUTHOR INDEX
Abadla, A. R., 197
Abbott, Frank S., 1383
Abdallah, Claude, 584
Acheampong, Andrew A., 708
Adams, Delyth A., 929
Adams, Paula C., 982
Ader, Jean-Claude, 813
Agen, Cristiana, 713
Aigbirhio, Franklin I., 832
Albet, Carlos, 976
Ali, Syed F., 881
Anari, M. Reza, 536
Anders, M. W., 48, 124, 875
Anderson, Christopher D., 1286
Anderson, Kathleen, 799
Andersson, Paul, 137
Andrews, Paul A., 178
Anglada, Lluis, 976
Angus, P. W., 485
Appleton, Martin L., 595
Arison, Byron H., 266
Astrom, Anders, 137
Atta-Asafo-Adjei, E., 1431
Augustijns, Patrick F., 1372
Baba, Takahiko, 1195
Bader, Augustinus, 1315
Bai, Xigeng, 993
Bailey, G. S., 965
Baker, Max T., 60
Balani, Suresh K., 185, 266, 688
Baron, Jeffrey, 1346
Barton, H. A., 1202
Bazin-Redureau, M., 1400
Beauchamp, Lilia, 1242
Bellward, Gail D., 1407
Bend, John R., 577
Benet, Leslie Z., 369, 825, 900,
1099
Benfenati, E., 113
Benoit, Etienne, 160
Bergeron, Raymond J., I 1 17
Besner, Jean Guy, 584
Bhagwat, Shripad V., 651
Bhalla, Kapil N., 506
Bhargava, Ravi, 1110
Bijloo, G. J., 667
Binienda, Zbigniew, 881
Binkley, Shelly N., 1231
Birner, Gerhard, 861
Bischer, Alfred, 900, 1099
Bishop, Warren P., 299
Blake, P., 433
Blake, Timothy, 799
Blanz, Joachim, 94
Boado, Ruben J., 55, 1297
Bocci, Guido, 713
Bockbrader, Howard N., 441
Boehlert, C. C., 1225
Bonfils, Claude, 1253
Borchardt, Ronald T., 1372
Born, Stephanie L., 702
Bornheim, Lester M., 825
Boudinot, F. Douglas, 655, 1368
Bowers, Gary D., 724
Boyd, Michael R., 651
Bozler, Gerhard, 1206
Bracken, William, 736
Bradbury, Alan, 393
Brady, Alexandra N., 60
Brashear, Wayne T., 1202
Brendel, K., 497
Brendel, Klaus, 327
Brennan, Beverley, 349
Brewer, T. 0., 1, 18
Brien, James F., 1248
Bugelski, Peter J., 1044
Buhler, Donald R., 1263
Bull, Richard J., 1412
Bullock, Peter, 736
Burka, Leo T., 232
Burke, M. Danny, 1274
Burlingame, Alma L., 369
Burmaster, Steve D., 631
Buronfosse, Thierry, 160
Busch, Ulrich, 1206
Buters, Jeroen T. M., 696
Cannell, Richard J. P., 724
Carbonaro, Michael A., 1044
Carlson, Timothy J., 749
Carrel, Barb K., 757
Cashman, John R., 1143
Castagnoli, Neal, Jr., 749
Castell, Jos#{233}V., 553
Castillo, Marta, 566
Castle, Pamela J., 1037
Catlow, John, 916
Cerniglia, Carl E., 1417
Chakravarty, Prasun K., 207
Chang, I. Y., 529
Chang, Tsun, 441
Chapelle, P., 1400
Chauret, N., 65, 1325
Chay, Sylvia H., 916
Chen, Guangping, 1346, 1390
Chen, 1-Wu, 266, 730
Chen, Roger, 207
Chenery, Richard, 349
Chenery, Richard J., 251
Cheng, Lawrence K., 631, 806
Cheraghali, A. Majid, 223
Chesson, S. M., 951
Chiba, Masato, 622
Chikai, Toshiyuki, 35
Ching, Michael S., 190
Chiu, Shuet-Hing Lee, 207, 1126
Cho, Arthur K., 201, 610
Cho, Joon H., 840
Cho, Joo Youn, 460
Cho, Yong-Baik, 1280
Choudhuri, Supratim, 1291
Choudhury, Ruksana, 314
Chouini-Lalanne, Nadia, 813
Chow, Moses S. S., 449
Christians, Uwe, 1315
Chu, Chung K., 655
Chu, Teresa Y. Y., 201
Chung, Woon-Gye, 1263
Clank, B., 922
Clarke, Stephen E., 251
Coassolo, P., 1051
Coldham, N. G., 501
Collins, Michael A., 102
Colthup, P. V., 1225
Conroy, Robert, 904
Cooper, A. E., 922
Coutts, Ronald T., 525
Creveling, Cyrus R., 430
Cribb, Alastair, 671
Cribb, Alastair E., 406, 536
Crom, William R., 1110
Crooks, Peter A., 1175
Crowl, Robert, 904
Crowley, Jan R., 786
Cutler, N. Shame, 595
Dahl, A. R., 529
Danesi, Romano, 713
Dannecker, Robert, 321, 327
Dave, M., 501
Davies, Donald S., 929
Davies, Malonne I., 1072
Davis, Charles B., 1028, 1044
Dawson, Michael J., 724
Dean, Dennis C., 1126
de Bruijn, E. A., 433
De Francesco, L., 197
De Graeve, Jean, 1305
de Groot, M. J., 667
DeHart, Peter D., 441
Dekant, Wolfgang, 861
Delatour, Paul, 160
de Leon, Jesus H., 1354
del Tacca, Mario, 713
de Miranda, Paulo, 1242
Demuth, Sandra 0., 1028
De Sousa, G., 1051
De Sousa, Georges, 308
Dickinson, Ronald G., 119
Dimova, Hnistina, 1117
Ding, Andreas, 369
di Paolo, Antonello, 713
Distefano, Emma W., 201, 610
Divakaruni, Prasanna, 295
Dixon, C. M., 1225
Dolan, M. Eileen, 1394
Domergue, Jacques, 1253
Donato, M. Teresa, 553
Draile, Henning, 1315
Draper, Alison, 736
Dreyer, Geoffrey, 799
Dubd, D., 1325
Ducharme, Y., 65
Duescher, Renee J., 846
Duffel, Michael W., 1346
Duha.rt, Benjamin, Jr., 1417
Dulik, Deanne M., 1004
Du Souich, Patrick, 279, 584
Dwoskin, Linda P., 1175
Dwyer, Lynn M., 688
1436
Eddershaw, Peter J., 724
Edwards, Robert J., 929
Ehlhardt, William J., 910
Ehninger, Gerhard, 94
Ekins, Sean, 1274
Elder, Cheryl A., 776
Elfarra, Adnan A., 846
Ellis, Andrew G., 363
Ellis, Joan D., 688
Ellis, Martin K., 102
El Mansouri, S., 227
Endo, Takahiko, 1022
Escousse, Andr#{233},343
Estabrook, R. W., 765
Evans, Frederick E., 1417
Evans, William E., 1 1 10
Facchine, Kevin L., 869
Fagliano, Jerald A., 607
Faiman, Morris D., 1153
Falany, Charles N., 945
Fasanmade, Adedigbo A., 573
Fasco, Michael J., 1339
Fedorov, Ivan I., 655
Fenselau, Catherine, 119
Ferrero, J. L., 765
Ferrero, James L., 1143, 1163
Finkelstein, Martin B., 124
Finley, Brent, 607
Fischer, VoWer, 327
Fisher, M. B., 1431
Fisher, Robert A., 415
Fisher, Robyn L., 327
Fong, Kei-Lai, 799
Fortin, R., 1325
Foster, David J. R., 892
Foumel-Gigleux, Sylvie, 1305
Franklin, Michael R., 1379
Fredenbung, Andrea M., 1178
Freeman, James P., 1417
Freemantle, Christopher A. J., 832
Freund, Stefan, 94
Friesen, R., 1325
Fujii, Y., 28
Fujikawa, A., 28
Fujio, Nami, 999
Fujioka, M., 28
Fujisawa, Masae, 1022
Fujita, Shoichi, 1268, 1301
Fujitsu, T., 28
Fukuyama, Takako, 779
Funae, Yoshihiko, 610, 999
Furst, Sylvia M., 590
Galceran, M. Teresa, 976
Gandolfi, A. J., 497
Ganguly, Tanmoy C., 945
Gargas, Michael, 607
Garland, William A., 904
Garton, Kyle J., 1426
Garver, Eric, 799
Geerts, Rita J. F., 216
Gerstenberg, B., 143
Ghabrial, H., 485
Ghabrial, Hany, 190
AUTHOR INDEX 1437
Gilard, Veronique, 813
Gullet, Gerard, 1253
Girard, Y., 1325
Gires, P., 1400
Gochield, Michael, 607
G#{243}mez-Lechdn, M. Jos#{233},553
Gonschior, Ann-Katrin, 1315
Gonzalez, Frank J., 696
Gordon, John D., 1383
Goudonnet, Herv#{233},343
Graham,P.J., 501
Green, Mitchell D., 299
Green, Trevor, 102
Griffin, D. A., 965
Griffin, Gear#{243}idP., 406
Griffm, Robert J., 232
Grimm, Scott W., 577
Guaitani,A., 197
Guengerich, F. Peter, 285, 438,
1315, 1339
Guertler, Joseph, 327
Guo, Zuyo, 438
Gupta, Elora, 1394
Gupta, N., 1085
Guzelian, Philip S., 415
Hackbarth, Ingelore, 1315
Hall, Caroline, 1383
Hall, M., 922
Hall, Tse Wai, 1188
Halm, Kathy A., 869
Halpert, James R., 577, 702, 1434
Hamaguchi, Tomoyuki, 35
Hamdoune, Mohamed, 343
Hansen, K. T., 667
Hanson, Beverly J., 441
Hara, Shuichi, 1022
Hardwick, James P., 696
Harlow, Greg R., 702
Harper, P. G., 433
Harrell, Andrew W., 251
Hart, Timothy K., 1028
Harvison, Peter J., 107
Hashmi, Mazzaz, 1362
Hata, T., 28
Hawksworth, Gabrielle M., 1274
Hayes, Karen A., 349
Hayes, Michael, 832
He, Minxia, 659
Heinzel, Gunther, 1206
Hendrickx, Jan, 354
Hepburn, Timothy W., 1028, 1044
Herber, Regine, 1305
Hercelin, Bernard, 1305
H#{233}roux,Lucie, 279
Herzyk, Danuta J., 1028
Heykants, Jos, 354
Heykants, Joseph J. P., 216
Heys, Richard, 799
Hickman, Dean, 473
Higaki, Kazutaka, 35
Highley, M. S., 433
Higuchi, Saburo, 1214
Hiratsuka, Akira, 201, 610
Ho, John, 757
Holland, Mary L., 90
Hollenberg, Paul F., 786
Honchel, Ronald, 398
Hook, Robert H., 631
Hone, Toshiharu, 999
Horton, M. N., 377
Hoshi, Hidenobu, 1301
Hosokawa, Masakiyo, 1022
Houston, J. Brian, 349, 393
Houtman, Jon, 398
Huang, Zeqi, 1339
Hughes, J. Michael B., 832
Huskey, Su-Er W., 1126
Ichimura, Fujio, 1220
Idowu, 0. R., 1, 18
Iga, Tatsuji, 718
Imaoka, Susumu, 999
Inazawa, Kazuhiru, 35
Innocenti, Federico, 713
Inoue, Katsuhiro, 430
Iwaki, Masahiro, 900, 1099
Iwasaki, K., 28
Iwata, Nobuhisa, 1022
Iyer, Krishna R., 749
Jaeck, D., 1051
Jamali, Fakhreddin, 240
Jarvi, Eric J., 1335
Jennerwein, Margreth, 178
Jeong, Hye Gwang, 285
Jesthi, Pradipta K., 595
Jimmo, Sandra L., 1248
John, Gilbert H., 702
Johnson, John T., 60
Johnson, Ted, 916
Jones, A. Daniel, 129, 422
Jones, Jeffrey P., 749
Jones, Terry, 832
Jdnsson, Gunilla, 137
Jordan, M. C., 922
Joseph, Gerald, 799
Juchau, Mont R., 72, 83, 1058
Jung, Ki Hwa, 460
Jusko, William J., 573
Kadlubar, Fred F., 518
Kadono, Kyoko, 35
Kaltenbach, M., 988
Kamata, Kazuo, 35
Kaminski, Donald R., 303
Kaminsky, Laurence S., 1339
Kane, Robert E., 303
Kang, Young-Sook, 55, 1297
Kapil, Ram P., 603
Kaschke, Siegfrid, 1206
Katashima, Masataka, 718
Kauffman, Laura R., 266, 688
Kawahara, Seiichi, 35
Kazusaka, Akio, 1268, 1301
Keller, Blandine, 321, 327
Kelly, C., 1
Kerr,B.M., 1225
Kestell, Philip, 363
Kharasch, Evan D., 490, 1426
Kim, Dae-Kee, 1280
Kim, Hyesook, 818
Kim,HyoJ., 840
Kim, Kelly Y., 825
Kim, Key H., 1280
Kim, S. G., 529
Kim, Sang Geon, 460
Kimelman, David, 72, 83
King, Andrew R., 119
Klaassen, Curtis D., 840
Kleiner, Heather E., 1136
Klekotka, Paul A., 1434
Knaggs, Andrew R., 724
Knaus, Edward E., 223
Kocarek, Thomas A., 415, 681
Kolars, Joseph C., 1315
Korzekwa, Kenneth R., 696
Kracko, D. A., 529
Kraft, Joan Creech, 72, 83, 1058
Krasny, Harvey C., 1242
Krasnykh, Victor, 945
Krenitsky, Thomas A., 1242
Kukulka, M. J., 765
Kukulka, Michael J., 1143
Kumagai, Yoshito, 610
Kumar, Gondi N., 506, 1286
Kumar, Rakesh, 223
Kummer, Michael, 1206
Kunze, Kent L., 490, 659
Kuo, Be-Sheng, 757
Kuo, Chung-Liang, 935
Kuo, George Y., 1004
Kwan, Eddie, 1383
Kwok, Deborah C., 1028
Labroo, Rita B., 490
La Du, Bert N., 935
Lake, B. G., 501
Lam, Gilbert N., 603
Lambert, C., 922
Lam#{233},Michael W., 129, 422
Lamiable, D., 988
Lampen, Alfons, 1315
Lang, Nicholas P., 518
Lash, Lawrence H., 846
Lau, Serrine S., 1136
Laurenzana, Elizabeth M., 271
Lavrijsen, Karel, 354
Lawton, M. P., 1431
Leclerq, M., 227
Lee, Daniel, 398
Lee, Heeyong, 285
Lee, Hye Suk, 285
Lee, R. D., 765
Leeson, Gerald A., 631
Leland, Michelle, 1028
Lemke, Leslie E., 559
Levine, Marc, 1407
Lewis, J. L., 529
Li, Albert P., 303
Li, C., 65, 1325
Li, Jianmin, 825
Li, Mm, 1175
Liberato, Daniel J., 904
Lin, Dong-Xin, 518
Lin, Jiunn H., 266, 730, 1008
Lin, Lena Y., 201, 610
Ling, Kah-Hiing J., 631
Lipe, George, 881
Lipscomb, J. C., 1202
Liu, Thao Chao, 246
Logan, C. J., 922
Loi, Cho-Ming, 1335
Loizou, George D., 875
Longin-Sauvageon, Christiane,
160
L#{248}nning,P. E., 377
Lorenzon, Giocondo, 308
Lu, D. Robert, 1368
Lu,Y.H., 154
Luchetta, Gabriel, 1117
Lunte, Craig E., 1072
Machinist, Joseph M., 1163
Macleod, Michael C., 854
Madan, Ajay, 1153
Madden, Stephen, 929
Madhu, Cherukury, 840
Maes, R. A. A., 433
Magdalou, Jacques, 343, 1305
Magistrelli, A., 1 13
Mahle, D. A., 1202
Malet-Martino, Marie-C., 813
Manchee, Gary R., 724
Mangold, James B., 615
Manouilov, Konstantine K., 655
Mansi, J., 433
Marchant, Nicola C., 1274
Marks, Gerald S., 1248
Martell, Karen J., 1354
Martinet, M., 1400
Martino, Robert, 813
Masgrau, Elisabeth, 887
Masmoudi, Taoufik, 343
Maspeis, L., 676
Masubuchi, Yasuhiro, 999
Masuda, Makihiko, 1268, 1301
Mathai, Leena, 266
Mather, Laurence E., 334
Mathews, Brad S., 757
Matsubara, Takashi, 1195
Matsuda, H., 28
Matsunaga, Tamihide, 261
Matsushita, Ryo, 1220
Maurel, Patrick, 1253
Maurer, Gerard, 321
Maurice, H#{233}l#{232}ne,279
Mautz, Douglas S., 513
Mayer, Michael D., 1163
McCague, R., 377
McClelland, R. A., 590
McClelland, Robert A., 246
McDonagh, Antony F., 369, 1099
McLaughlin, Brian E., 1248
McLean, Cohn F., 334
McMillan, Joellyn M., 1286
McNally, William P., 441
McNamara, Patrick J., 465
McQueen, Charlene A., 559
Mehta, Samir C., 1368
1438 AUTHOR INDEX
Mehvar, Reza, 637
Meinwald, Jerrold, 1426
Merdink, James L., 1037
Meuldermans, Willem, 354
Meuldermans, Willem E. G., 216
Meurer, Kathryn A., 1178
Meyer, Em, 321
Miller, Randall R., I I 26
Miller, Randy R., 266
Milne, Robert W., 334
Mizsak, Steven A., 383
Modest, E. J., 1 13
Modi, Marlene W., 776
Momerency, G., 433
Monbaliu, Johan, 354
Monks, Terrence J., I 136
Monshouwer, M., 44
Monshouwer, Mario, 542
Moore, A. S., 501
Morgan, D. J., 485
Morgan, Denis 3., 190
Morgan, S. E., 497
Morin, Dexter, 422
Morin, E., 988
Moroni, Patricia, 160
Mounie, Jacques, 343
Mugford, Cheryl A., 290
Mulford, D. J., 765
Murray, Graeme I., 1274
Murry,DarylJ., 1110
Mutlib, A. E., 951
Nadeau, Rosemary W., 904
Nagase, K., 28
Nakagawa, Terumichi, 779
Nakamura, Akio, 1268
Nakano, Masayuki, 35
Nakashima, Em, 1220
Nakatsu, Kanji, 1248
Nardini, Denise, 713
Narimatsu, Shizuo, 610, 999
Nation, Roger L., 334
Nau, Heinz, 887
Naylor, Jacky L., 102
Neighbors, Suzanne M., 548
Nellans, Hugh N., 149
Nelson, Wendel L., 513
Newton, Deborah J., 154
Ng, C. Y., 485
Ngo, Leock Y., 525
Nguyen, Ann C., 1099
Nichols, William K., 595
Nicolas, Florence, 308
Nicoll-Griffith, D., 1325
Nicoll-Griffith, D. A., 65
Nicoll-Griffith, D. A., 1085
Nijmeijer, S. M., 44
Nijmeijer, Sandra M., 542
Nikula, K. J., 529
Norton, Robin, 607
Novak, R. F., 529
Novak, Raymond F., 681, 818
Nuss, Cindy, 671
Nyarko, Alexander K., 107
Ohshima, Tohru, 1220
Okita. Janice Rice, 1037
Okita, Richard T., 1037
Olson, Michael J., 60
Olsson, Per, 832
Ortiz Dc Montellano, Paul R.,
1181
Ostovic, Drazen, 730
Ouellet, Dani#{233}leM.-C., 478
Overhauser, Joan, 398
Owens, S. Michael, 271
Page, Brian C., 832
Palamanda, hiram R., 473
Pang, K. S., 166
Pang, K. Sandy, 255, 622
Pardridge, William M., 55, 1297
Park, B. Kevin, 929
Park, G. R., 1225
Parker, Jean C., 846
Parker, William B., 881
Parkinson, Andrew, 736, 1 153
Patanella, James E., 869
Patel, Nita J., 124
Paustenbach, Dennis J., 607
Payne, A. K., 497
Pearce, Robin, 736
Pearson, Paul 0., 383
Peggins, J. 0., 1, 18
Perotti, Beatrice Y. 1., 825
Perret, G., 227
Perrin,John, 1117
Peterson, Lisa, 749
Petitjean, 0., 227
Phillips, Diane L., 664
Phillips, L. R., 676
Philpot, R. M., 1431
Pichard, Lydiane, 1253
Pike, Victor W., 832
Pinaire, J. A., 642
Piquette-Miller, Micheline, 240
Pitzenberger, Steven M., 185, 688
Placidi, Michel, 308
Podoll, Terry, 490
Podval, Jordan, 736
Pohland, Raymond C., 916
Poklewska-Koziell, Margo, 1248
Pollack, Gary M., 478
Poon, 0. K., 377
Poon, Karen, 255
Porter,Carl, 1117
Porthault, M., 227
Potts, William, 799
Poulsen, L. L., 1390
Powell, K. Leslie, 854
Pritchard, J. Frederick, 90
Prough, R. A., 642
Prueksantanont, Thomayant, 688
Qing, Wei-Guo, 854
Radulovic, Louis L., 441
Rahmani,R., 1051
Rahmani, Roger, 308
Ramachandran, C., 65
Ramjit, Harri G., 185
Rasmusson, Gary H., I 126
Ravindranath, Vijayalakshmi, 651
Reddick, Wilburn E., 1110
Reddy, Satya, 818
Reith, M. Kelly, 63 1 , 806
Renner, Ulf, 94
Renton, Kenneth W., 536
Rettie, A. E., 1431
Rewcastle, Gordon W., 363
Reynolds, James, 637
Rho, Jung Koo, 285
Rhodes, Christopher G., 832
Rhodes, Gerald R., 1028
Richards, Lauren E., 600
Richmond, H., 922
Rickert, Douglas E., 982
Riggs, K. Wayne, 1383
Riley, R. J., 922
Ring, John A., 190
Roberts, Stephen M., 664
Rodrigues, A. D., 642, 765
Rodrigues, A. David, 1 143, 1163
Rodriguez, Lolita C., 615
Rojas, Katherine, 398
Romkes-Sparks, Marjorie, 473
Ronnenberg, William C., Jr., 60
Rose, James Q., 757
Rose, Lucy M., 881
Rosebrough, Scott F., 1362
Roy, Sandip K., 1394
Rozman, Elena, 976
Ruenitz, Peter C., 993
Runciman, William B., 334
Runge-Morris, Melissa, 455
Rurak, Dan W., 1383
Rutten, Albert J., 334
Sakuma, S., 28
Sallustio, Benedetta C., 892
Salmona, M., 1 13
Sandberg, Jennifer A., 881
Sanders, Ruth A., 1094
Sass, J#{246}mOliver, 887
Sastry, Sunita G., 1094
Sato, A., 28
Sato, Yoshinobu, 1022
Satoh, Hiroko, 904
Satoh, Tetsuo, 1022
Sauer, M. J., 501
Saurat, Jean-Hilaire, 887
Savrin, Jonathan E., 607
Sawada, Yasufumi, 718
Schaefer, William H., 1044
Scheide, Sallie, 904
Schepers, G., 143
Scherrmann, J. M., 1400
Schiller, C. D., 1051
Schmid, Jochen, 1206
Schmitz, Debra A., 201
Schreier, Katherine M., 1 1 17
Schuetz, Em G., 415
Schwartz, Michael S., 185
Segall, H. J., 422
Semple, Hugh A., 794
Serabjit-Singh, C. J., 1225
Sewing, Karl-F., 1315
Shackleton, Martha, 708
Sharer, Jane E., 1231
Shen, Danny D., 513
Shet, M. S., 765
Shet, Manjunath S., 1163
Shimamoto, Yoshinori, 1301
Shimatani, K., 28
Shipley, Lisa A., 1231
Shiraga, T., 28
Shore, Leonard J., 119
Shou, Magang, 696
Shu, Arthur, 799
Shulkes, Arthur, 190
Sidebottom, Philip J., 724
Sim, Edith, 473
Singh, Surinder, 314
Sivapathasundaram, S., 501
Skinner, Thomas L., I 178
Sladek, Norman E., 1080
Slikker, William, Jr., 881
Small, David S., 465
Smallwood, R. A., 485
Smallwood, Richard A., 190
Smith, Brian R., 1044
Smith, Philip C., 566
Some, William H., 548
Somogyi, Andrew A., 334
Sorrels, Shannon L., 271
Spaldin, Vanessa, 929
Spielberg, Stephen P., 406
Sproles, G. Douglas, 806
Sreerama, Lakshmaiah, 1080
Stable, Paul L., 90
Stearns, Ralph A., 207, 266
Steenwyk, Rick C., 383
Stem, Alan H., 607
Stevens, Douglas K., 1412
Stoica, George, 854
Streeter, Anthony J., 90
Streiff, Richard R., 1117
Stresser, D. M., 965
Strom, Stephen C., 415
Strupczewski, J. T., 951
Stuhler, John D., 757
Stumpf, Walter E., 885
Sugimoto, Tchihiro, 1268
Sugiura, Munetoshi, 718
Sukhai, Pratima, 590
Sun, He, 449
Sun, Jung-Hui, 600
Supko, J. 0., 676
Surber, B. W., 765
Sutherland, Derek R., 724
Suzuki, Tokuji, 610, 999
Svenson, Craig K., 295
Swanson, Steven P., 916
Sweeny, David J., 149
Szumlanski, Carol, 398
Szumlanski, Carol L., 854
Tacconi, M. T., 113
Taguchi, Tadao, 1305
Takacs, Adrienne R., 90
AUTHOR INDEX 1439
Takahashii, Chikako, 999
Takeuchi, Masaharu, 35
Tam, Yun K., 525
Tanaka, Eiji, 48
Tang-Liu, Diane D-S., 708
Tanner, Richard J. N., 832
Tarbit, M. H., 1225
Tarloff, Joan B., 290
Tasaki, Takafumi, 1268
Taylor, Wesley G., 1188
Tebbett, Ian R., 664
Tephly, Thomas R., 299
Terry, Christi M., 595
Theoharides, Anthony D., 688
Thdnot, Jean-Paul, 1253
Thomas, Pascal, 308
Thomas, Paul, 736
Thomas, Paul E., 1291
Thomas, S. B., 765
Thompson, Wayne J., 185
Thummel, Kenneth E., 490, 1426
Tod, M., 227
Tokuma, Y., 28
Touchi, Akira, 1195
Trager, William F., 490, 659, 749
Trenque, 1., 988
Trimble, L., 1325
Trimble, L. A., 65
Trimble, L. A., 1085
Tsuji, Akira, 1220
Tsuruda, Laurie S., 129
TOrck, Dietrich, 441
Twa, S. P., 1085
Tynes, Ronald E., 321
Uetrecht, Jack P., 246, 590
Unadkat, Jashvant D., 473
Urbanski, James J., 1028, 1044
Usui, Takashi, 1214
Valles, B., 1051
Van Beijsterveldt, Ludy E. C., 216
Van Cantfort, Jacques, 1305
Van Cauwenberghe, K., 433
Vandenbranden, Mark R., 1231
Vanderbeck, Scott M., 1291
Van Dyck, Dirk, 354
Van Horn, Robert, 799
Van Houdt, Jos, 354
van Leengoed, L. A. M. G., 44
Van Miert, A. S. J. P. A. M., 44
Van Miert, Adelbert S. J. P. A. M.,
542
Van Oosterom, A. T., 433
Varga, Sandor L., 688
Vastag, Kari J., 730
Vatsis, Kostas P., 1354
Vedres, Darrell D., 1188
Veltman, James, 736
Veltman, James C., 1094
Vento, Colleen, 455
Ventresca, G. Pietro, 832
Verheijden, J. H. M., 44
Vermeulen, N. P. E., 667
Vestal, Robert E., 1335
Vickers, Alison E. M., 321, 327
Vickers, Stanley, 1007
Viger-Chougnet, A., 1051
Villa, P., 113
Vistelle, R., 988
Vdlkel, H., 143
Vollmer, K. Otto, 441
Voncken, P., 143
von Hodenberg, Albrecht, 441
Vyas, Kamlesh P., 1104
Waidelich, Dietmar, 94
Walle, Thomas, 506, 1286
Walle, U. Kristina, 506
Walsh, John S., 869
Walter, B., 377
Wang, Jianyao, 1286
Wang, Regina, 671
Wang, Regina W., 154
Wang, Y. Karen, 615
Wang, Ying, 60
Ward, Alison, 473
Ware, Joseph A., 295
Waskiewicz, Mark J., 1291
Watanabe, Kazuhito, 261
Watanabe, Takashi, 1214
Waterhouse, Ian, 724
Waters, Stephen L., 832
Watkins, John B., HI, 1094
Watkins, Paul B., 1315
Weber, Wendell W., 1354
Webster, Lorraine K., 363
Wei, Xiaoxiong, 1335
Weimar, William R., 1117
Weinshilboum, Richard M., 398,
854
Werner, Michael, 861
White, Catherine A., 655
Wiebe, Leonard I., 223
Wieben, Eric D., 398
Wiegand, Jan, 1117
Wienkers, Larry C., 383
Williams, D. E., 965
Williams, H., 1085
Williams, J. Andrew, 1274
Wilson, Dennis W., 422
Witkamp, R. F., 44
Witkamp, Renger F., 542
Woestenborghs, Robert, 354
Woestenborghs, Robert J. H., 216
Woodcroft, Kimberley J., 681
Woodland, Joseph M., 910
Worboys, Philip D., 393
Wrighton, Steven A., 1037, 1231
Wu, Dafang, 1297
Wuyts, Koen, 216
Wyss, R., 1051
Xia, Fangming, 794
Xiao, 0.-H., 642
Xu, Guihong, 1412
Xu, Yuping, 846
Yamaguchi, Yoshitaka, 1195
Yamamoto, Ikuo, 261
Yamamoto, Koujirou, 718
Yamamoto, Yukio, 1268, 1301
Yamaoka, Kiyoshi, 779
Yamazaki, Hiroshi, 438
Yao,GuoWei, 1117
Yashimura, Hidetoshi, 261
Yasui, Hiroyuki, 779
Yergey, J., 1325
Yergey, J. A., 65
Yergey, J. A., 1085
Yeselwaram, K., 159
Yokel, Robert A., 1178
Yost, Garold S., 595
Yuen, Peter, 1426
Yukawa, Tadahiku, 35
Yun, Chul-Ho, 285
Zangar, R. C., 529
Zangar, Richard C., 681
Zeller, Klaus-Peter, 94
Zhang, Donglu, 1417
Zhang, Kanyin E., 1104
Zhang, Xu-Jie, 1291
Zhang, Zhiyi, 1339
Zia-Amirhosseini, Parnian, 369,
900
Ziegler, D. M., 1390
1440
SUBJECT INDEX
Abbot-66193, metabolism, liver cytochrome P450 enzymes involved in,
identification of (humans), 1163
ABT-077, see Zileuton
ABT-418, in vitro hepatic metabolism, pattern of microsomal flavin-
containing monooxygenase-dependent stereoselective N -oxidation
(chimpanzees), 1143
Acetaminophen
glutathione depletion kinetics, simulation study, 622
in vitro bioactivation, contribution of oxidation and deacetylation, liver
and kidney (rats), 290
sulfation and glucuronidation, cultured hepatocytes (humans), 303
Acetylation
role in mutagenicity of hydralazine, 559
slow, caused by labile and catalytically impaired mutant N- acetyltrans-
ferase (mice), 1354
N-Acetylation, role in susceptibility to 2,3,5-(triglutathion-S-yl)hydroqui-
none-mediated nephrotoxicity, 1136
Acetyl coenzyme A:arylamine N-acetyltransferase, comparison of activity
in liver, kidney, and intestine (rats), 295
N-Acetyltransferase (NAT2 9), labile and catalytically impaired mutant,
cause of slow acetylation (mice), 1354
Acidic drugs, peritoneal membrane transport, physiological pharmacoki-
netic concepts, 1220
Acitretin, elimination, rats pretreated with phenobarbital or (3- naphthofla-
vone, 465
Actinobacillus pleuropneumoniae, infection, suppression of oxidative he-
patic drug metabolism and cytochrome P4503A mRNA levels
(pigs), 44
Acyl glucuronides, ibuprofen and ibufenac, disposition and reactivity
(monkeys, humans), 566
AL-1576, minimal effects on xenobiotic transformation, after subacute
topical-ocular dosing (rabbits), 1094
AL-41 14, minimal effects on xenobiotic transformation, after subacute
topical-ocular dosing (rabbits), 1094
Albendazole, chiral sulfoxidation, liver microsomes (rats), 160
Albumin, human serum
disposition and reactivity of ibuprofen and ibufenac acyl glucuronides,in vitro, 566
reactivity of tolmetin glucuronide with, identification of binding sites
and mechanisms of reaction, 369
stereoselective reversible binding properties of glucuronide conjugates
of fenoprofen enantiomers to, 900
Alcohol (hydroxysteroid) sulfotransferase, and aryl sulfotransferase IV,
intralobular localizations and distributions, enzyme- and sex-spe-
cific differences, liver (rats), 1346
Aldehyde oxidase, role in in vitro conversion of famciclovir to penciclo-
vir, liver (humans), 251
Aldehyde oxygenase, cytochrome P450-dependent, catalyzes oxidation of
tolualdehydes to toluic acids, liver (mouse), 261
Aldehydes, catalyzed by liver flavin-containing monooxygenase, oxida-
tion (pigs), 1390
ALDH-3, see Cytosolic class 3 aldehyde dehydrogenase
Aldose reductase inhibitors, minimal effects on xenobiotic transformation,
after subacute topical-ocular dosing (rabbits), 1094
Alfentanil, metabolism, catalytic role of cytochrome P450 3A4, 490
Amines, nonmacrolide, cytochrome P450 metabolic-intermediate com-
plex formation, enhanced rates, rifampicin-treated liver micro-
somes (rabbits), 1379
Amino acids, interaction with propranolol, single-pass isolated, perfused
liver (rats), 794
1-Aminobenzotriazole, N-aralkylated derivatives, inactivation of hepatic
cytochromes P450 2B4 and 2B5, selectivity and kinetics (rabbits),
577
2-Amino-l-methyl-6-phenylimidazo[4,5-b}pyridine, biotransformation by
hepatic microsomes and cytosols, species differences (humans,
rats, mice), 5 18
8-Aminoquinoline
antiparasitic agents, metabolism, side-chain hydroxylation, 18
WR 238605, metabolism, liver microsomes (rats), 1
5-Aminosalicylic acid, oxidation by hypochlorous acid to reactive imino-
quinone, possible role in treatment of inflammatory bowel dis-
eases, 246
Amitriptyline, biotransformation by Cunninghamella elegans, 1417
Angiotensin II antagonist, GR117289, microbial biotransformation by
Streptomyces rimosus to identify mammalian metabolite, 724
Angiotensin H receptor antagonists, see DMP 81 1; Losartan
Antibiotics, tiamulin, induction and inhibition of cytochrome P450 3A,
studies in primary hepatocyte cultures and liver microsomes (pigs),
542
Antibodies
antipeptide, against overlapping sequences differentially inhibit
CYP2D6 (humans), 671
antipeptide, dog cytochrome P450 isozyme belonging to CYP2D sub-
family, development (dogs), 1268
antipeptide, targeted against specific regions of rat CYP2D1 and human
CYP2D6, 271
respiratory syncytial virus-specific reshaped monoclonal antibody
RSHZ19, preclinical pharmacokinetic evaluation, 1028
Anticonvulsant, novel, remacemide hydrochloride, induction of rodent
hepatic drug-metabolizing enzyme activities, 922
Antiglaucoma medication, novel, prostaglandin derivative, ocular absorp-
tion, distribution, and systemic absorption (rabbits), 35
Antihypertensive agents, hydralazine, mutagenicity, role of acetylation,
559
Antimalarial drugs
candidate, WR 238605, metabolism, liver microsomes (rats), 1
formation of methemoglobin, improved pharmacodynamic model, 573
Antimycotic agents, expression of microsomal epoxide hydrolase gene
(rats), 460
Antineoplastic agent, investigational, perillyl alcohol, oral administration,
pharmacokinetics of active drug metabolites (dogs), 676
Anti-opportunistic infection drugs, interaction with dapsone (humans),
473
Antiparasitic agents, 8-aminoquinoline, metabolism, side-chain hydroxy-
lation, 18
Antipeptide antibodies
against overlapping sequences differentially inhibit CYP2D6 (humans),
671
dog cytochrome P450 isozyme belonging to CYP2D subfamily, devel-
opment (dogs), 1268
targeted against specific regions of rat CYP2D1 and human CYP2D6,
271
Aralkyl sulfides, short-chain, (S)-sulfoxidation, selectivity of flavin-con-
taming monooxygenase 5, 1431
Arthritis, adjuvant, ketoprofen-treated and untreated, influence of severity
of inflammation on disposition kinetics of propranolol enanti-
omers, 240
Arylamine N-acetyltransferases, dapsone acetylation, liver (humans), 473
Aryl sulfotransferase IV, and alcohol (hydroxysteroid) sulfotransferase,
intralobular localizations and distributions, enzyme- and sex-spe-
cific differences, liver (rats), 1346
Autoradiography, radioassay combined with, utility, tissue distribution
studies and cytopharmacology, 885
3 -Azido-3 -deoxythymidine
comparative metabolism, cultured hepatocytes (rats, dogs, monkeys,
humans), 308
lymphatic distribution (mice), 655
3 -Azido-2,3 -dideoxyuridine, lymphatic distribution (mice), 655
SUBJECT INDEX 1441
Baculovirus, cDNA-directed expression of cytochrome P450 lAl (hu-
mans), 696
Benzoic acid glycine, conjugation, isolated perfused kidney (rats), 255
O-Benzylguanine, pharmacokinetics and metabolism by liver microsomes
(rats), 1394
Benzyloxyresorufin, as specific substrate for cytochrome P450 2B 11
(dogs), 1434
Biantrazole, two regioisomeric monocarboxylic acid metabolites excreted
in urine (humans), 600
Bile
excretion of morphine-3-glucuronide (rats), 478
excretion of pyrrolic metabolites of [‘4C]monocrotaline (rats), 422
excretion of verlukast, 1085
Biodistribution, 67Ga deferoxamineacetyl-cysteinylbiotin, 1362
Bisphosphonate, YM175, pharmacokinetics (rats, dogs), 1214
Biotransformation, amitriptyline, by Cunninghamella elegans, 1417
Blood, cocaine concentrations, increased with ethanol cotreatment (mice),
Brain
664
cocaine concentrations, increased with ethanol cotreatment (mice), 664
cytochrome P450, levels, reassessment (rats), 651
nicotine metabolites, determination of, after peripheral radiolabeled
nicotine administration (rats), 1175
tetrahydrocannabinol metabolites, kinetics, effect of cannabidiol pre-
treatment (mice), 825
Breast cancer, patients on long-term therapy, identification of tamoxifen
metabolites, 377
Brimonidine, comparative ocular pharmacokinetics after single-dose ap-
plication, albino and pigmented rabbits, 708
Bromodichloroacetate, metabolism (B6C3F1 mice), 1412
Budesonide, metabolism by cytochrome P450 3A enzymes, liver (hu-
mans), 137
Bufuralol, regioselective and stereoselective oxidation, catalyzed by mi-
crosomes containing cDNA-expressed P4502D6 (humans), 513
Caffeine, in vivo disposition, predicted from hepatic microsomal and
hepatocyte data, 349
Cannabidiol, pretreatment, effect on kinetics of tetrahydrocannabinol me-
tabolites, brain (mice), 825
Carbamazepine, oxidative metabolites, covalent binding to neutrophils,
590
Carbon tetrachloride, liver intoxication by, effect on hepatic local dispo-
sition of oxacillin, 779
Carboxylesterase
levels, liver microsomes, interindividual variation (humans), 1022
nasal, induction following inhalation exposure to pyridine (rats), 529
Catechol-O-methyltransferase, induction in luminal epithelium of uterus
by progesterone, inhibition by RU-486 (rats), 430
CCK-B antagonist, LY288513, 0-glucuronide metabolite, characteriza-
tion and plasma levels (mice, rats, dogs), 910
CD4, recombinant human soluble, renal catabolism after intravenous
administration (rats), 1044Chemopreventive agent, 2,6-dithiopurine, toxicity and metabolism (mice),
854
Chiral sulfoxidation, albendazole, liver microsomes (rats), 160
Chloride, intracellular, effect on cellular pharmacodynamics of cis-diam-
minedichloroplatinum(II), 178
Chlorodifluoroethene, interaction with isoflurane, liver microsomes, role
of cytochrome P4502B6 in potentiation of haloethene metabolism
(humans), 60
Chloroethylamine, formation following ifosfamide administration (hu-
mans), 433
2-Chloro-1,l,2-tetrafluoroethane, see HCFC-124
l-Chloro-2,2,2-trifluoroethane, see HCFC133a
S-(2-Chloro-1,1,2-trifluoroethyl)glutathione, biosynthesis, hepatocytes
and Hep 02 cells (rats, humans), 48
Chlorzoxazone 6-hydroxylation, selectivity of cytochrome P4502E1, 438
Chromium, screening, urine (letters to the editor), 607
CI-937, biotransformation, hepatocytes (rats), 94
Cicletamne, urinary excretion, stereochemical aspects (rats), 988
Cimetidine, effect on hepatic cytochrome P450, evidence for formation of
metabolite-intermediate complex, 1407
Ciprofibrate, enhanced expression of cytochrome P450 2El and 2B1/2B2,
primary cultured hepatocytes (rats), 681
Ciprofloxacin, disposition, isolated perfused liver (rats), 197
Clearance, drug, liver volume as determinant, children and adolescents,
1110
Clethrionomys rufocanus, wild, debrisoquine/sparteine-type polymorphic
drug metabolism, 1301
Clofibric acid, glutathione conjugate, characterization and formation, 119
Cocaine, concentrations, blood and brain, increased with ethanol cotreat-
ment (mice), 664
Cotinine, accumulation, pigmented and unpigmented hair (rats), 143
Cunninghamella elegans, biotransformation of amitriptyline, 1417
Cyclosporin derivative, see SDZ 1MM 125
Cyclosporin 0, metabolism (mice, rats, dogs), 615
Cysteine, infusion, in vivo modification of 3 -phosphoadenosine 5 -
phosphosulfate and sulfate, 840
Cytochrome P450
activities, hepatocytes in primary culture, effect of model inducers
(humans), 553
-catalyzed oxidation of (S)-nicotine, stereoselectivity and isotope ef-
fects, 749
constitutive hepatic, inactivation by phencyclidine (rats), 201
-dependent aldehyde oxygenase, catalyzes oxidation of tolualdehydes to
toluic acids, liver (mouse), 261
-dependent monooxygenases, chiral sulfoxidation of albendazole, liver
microsomes (rats), 160
downregulation by polyinosinic acid-polycytidylic acid, influence of
duration of induction and species, 536
enzymes
liver, involved in metabolism of zileuton and its N- dehydroxylated
metabolite (humans), 1163
responsible for sulfoxidation of S-methyl N,N- diethylthiolcarbam-
ate, identification of (humans, rats), 1153
hepatic, effect of cimetidine, evidence for formation of metabolite-
intermediate complex, 1407
human liver, oxidative metabolism of zolpidem, 1253
inhibitors, evaluation of specificities, in vitro metabolism of therapeutic
agents, liver microsomes (humans), 154
induction, liver microsomes (monkeys), 736
isoenzymes, metabolism of mofarotene, hepatocytes and liver micro-
somes, different species, 1051
isozymes
dog, belonging to CYP2D subfamily, purification, characterization,
and development of its antipeptide antibody, 1268
inhibition and induction after repetitive administration of imipramine
(rats), 999
“male-specific,” induction of, in female rats, by oxandrolone, 1291
responsible for in vitro oxidative metabolism of finasteride, identifi-
cation of (humans), 1126
levels, brain, reassessment (rats), 651
metabolic-intermediate complex formation from nonmacrolide amines,
enhanced rates, rifampicin-treated liver microsomes (rabbits), 1379
metabolism of tacrolimus in small intestine, 1315
multiple forms, involved in metabolism of ondansetron (humans), 1225
structure, mechanism, and inhibition, 1181
Cytochrome P450 lAl
1442 SUBJECT INDEX
activity, liver, inhibitors, relative potency of mexiletine, lidocaine, and
tocainide (rats), 1335
cDNA-directed expression using baculovirus, purification, dependency
on NADPH-P450 oxidoreductase, and reconstitution of catalytic
properties without purification (humans), 696
expression in renal tissue, 3-methylcholanthrene and pyridine effects
(rats), 818
R-warfarin metabolism as probe (humans), 1339
Cytochrome P450 lA2
expression in renal tissue, 3-methylcholanthrene and pyridine effects
(rats), 818
hepatic, in vitro activity, determination, use of tacrine as isoenzyme-
specific probe (humans), 929
R-warfarin metabolism as probe (humans), 1339
Cytochrome P450 2B 1
liver, mechanism-based inactivation by phencycidine and iminium ion
(rats), 786
xenobiotic-enhanced expression, primary cultured hepatocytes (rats),
681
Cytochrome P450 2B2, xenobiotic-enhanced expression, primary cultured
hepatocytes (rats), 681
Cytochrome P450 2B4, inactivation by N-aralkylated derivatives of
l-aminobenzotriazole, selectivity and kinetics (rabbits), 577
Cytochrome P450 2B5, inactivation by N-aralkylated derivatives of
1-aminobenzotriazole, selectivity and kinetics (rabbits), 577
Cytochrome P450 2B6, role in potentiation of haloethene metabolism, 60
Cytochrome P450 2B 11
benzyloxyresorufin as specific substrate for (dogs), 1434
cytochrome P450 PBD-21P450 2B 1 1, progesterone 21-hydroxylase ac-
tivity, characterization through reconstitution, heterologous expres-
sion, and site-directed mutagenesis (dogs), 702
Cytochrome P450 2C, subfamily members
biotransformation of losartan, liver microsomes (humans), 207
N4-hydroxylation of sulfamethoxazole, hepatic microsomes (rats, hu-
mans), 406
Cytochrome P450 2C11, in vitro metabolism of tirilazad mesylate (rats),
383
Cytochrome P450 2D
isozymes, catalysis of 4-hydroxylation of methamphetamine enanti-
omers, 610
subfamily, dog cytochrome P450 isozyme belonging to, purification,
characterization, and development of its antipeptide antibody, 1268
Cytochrome P450 2D1, antipeptide antibodies targeted against specific
regions (rats), 271
Cytochrome P450 2D6
antipeptide antibodies against overlapping sequences differentially in-
hibit (humans), 671
antipeptide antibodies targeted against specific regions (humans), 271
cDNA-expressed, microsomes containing, catalytic role, regioselective
and stereoselective oxidation of metoprolol and bufuralol (hu-
mans), 513
-dependent oxidation of GBR 12909, computer prediction and experi-
mental validation, 667
Cytochrome P450 2El
liver, stereoselective metabolism of enflurane (humans), 1426
selectivity, chlorzoxazone 6-hydroxylation, 438
xenobiotic-enhanced expression, primary cultured hepatocytes (rats),
681
Cytochrome P450 3A
biotransformation of SDZ 1MM 125, liver (humans), 321
enzymes, metabolism of budesonide, liver (humans), 137
induction, hepatocyte primary cultures, comparative analysis (rats, rab-
bits, humans), 415
induction and inhibition by tiamulin, primary hepatocyte cultures and
liver microsomes (pigs), 542
mRNA levels, infection-mediated suppression (pigs), 44
subfamily members, role in biotransformation of losartan, liver micro-
somes (humans), 207
Cytochrome P450 3Al/2, role in sex-specific sulfoxidation of N- acetyl-
S-(pentachlorobutadienyl)-L-cysteine (rats), 861
Cytochrome P450 3A4
catalytic role, multiple pathways of alfentanil metabolism, 490
metabolism of terfenadine, hepatic microsomes (humans), 631
purified recombinant fusion protein containing, in vitro metabolism of
terfenadine, 765
role in formation of EXP3174, oxidation of losartan, liver microsomes
(humans), 285
Cytochrome P450 PBD-21P450 2B 1 1, progesterone 21-hydroxylase ac-
tivity, characterization through reconstitution, heterologous expres-
sion, and site-directed mutagenesis (dogs), 702
Cytopharmacology, relevance, utility of radioassay combined with auto-
radiography, 885
Cytosol, metabolism of dichloroacetic acid, 1202
Cytosolic class 3 aldehyde dehydrogenase (ALDH-3), obtained from
tumor cells and normal tissue, human breast adenocarcinoma
MCF-7/0 cells electroporated with, differential sensitivity to
mafosfamide, 1080
Dapsone, acetylation, liver arylamine N-acetyltransferases, and interac-
tion with anti-opportunistic infection drugs (humans), 473
N-Deacetylation, role in susceptibility to 2,3,5-(triglutathion-S- yl)hydro-
quinone-mediated nephrotoxicity, 1136
Debrisoquine/sparteine-type polymorphic drug metabolism, wild Clethri-
onomys rufocanus, 1301
67Ga Deferoxamineacetyl-cysteinylbiotin, synthesis, pharmacokinetics,
and biodistribution, 1362
Delta sleep-inducing peptide, transport and metabolism, cultured intestinal
epithelial cell monolayers (humans), 1372
DETC-Me, see S-Methyl N,N-diethylthiolcarbamate
Dexamethasone, induction of taxol metabolism (rats), 1286
Diabetes, streptozotocin-induced, effects on liver sulfotransferase gene
expression (rats), 455
cis-Diani.minedichloroplatinum(H), cellular pharmacodynamics, effect of
intracellular chloride, 178
Dichloroacetic acid, metabolism in cytosol, 1202
l,l-Dichloro-2,2-bis(p-chlorophenyl)ethane, control of cytotoxicity, oxi-
dation at C-l, lung cells (rabbits, humans), 595
N-(3,5-Dichlorophenyl)succinimide, metabolism, isolated hepatocytes
(rats), 107
[‘4C]- and [35S]S-(l,2-Dichlorovinyl)-L-cysteine, metabolism (rats), 124
2 , 3 -Dideoxycytidine, placental transfer and fetal disposition (monkeys),
881
2 , 3 -Dideoxyinosine, placental transfer and fetal disposition (monkeys),
881
N,N-Diethylbenzamide, metabolites, detection in urine, NMR spectros-
copy (rats), 1188
Diethyl ether, lack of residual effects on lidocaine metabolism, single-pass
isolated liver perfusion system (rats), 525
N’,N’ ‘-Diethylnorspermine, metabolism and pharmacokinetics, 1117
5,6-Dimethylxanthenone-4-acetic acid, metabolism and elimination, iso-
lated perfused liver (rats), 363
[‘4C]1,3-Dinitrobenzene, metabolism by small intestine mucosa in vitro
(rats), 982
6,8-Dioxabicyclo[3.2.l}octanyl moiety, role in microsomal metabolism of
5-lipoxygenase inhibitors, 1325
Disulfiram, bioactivation, terminal step, 1153
2,6-Dithiopurine, toxicity and metabolism (mice), 854
DMP 811 (L-708,404), disposition (rats, monkeys, chimpanzees), 1 104
SUBJECT INDEX 1443
Dolasetron mesylate, metabolism (humans), 806
DuP 734, pharmacokinetics and presystemic first-pass elimination (rats),
603
DuP 941 , two regioisomeric monocarboxylic acid metabolites excreted in
urine (humans), 600
Ebrotidine, metabolism, urine, investigation by liquid chromatography-
atmospheric pressure chemical ionization mass spectrometry (hu-
mans), 976
Enflurane, stereoselective metabolism, liver cytochrome P450 2E1 (hu-
mans), 1426
Enzymes, hepatic, activities, phase I and phase II in vitro, comparison
(humans, dogs, rhesus monkeys, cynomolgus monkeys), 1231
Epoxide hydrolase gene, microsomal, differential expression by imidazole
and triazole antimycotic agents (rats), 460
ET18-OMe, fate in malignant cells, normal cells, and isolated and per-
fused rat liver, 113
Ethanol, cotreatment with, increased blood and brain cocaine concentra-
tions (mice), 664
Ethoxycoumarin, rates of oxidation, liver slices (rats), 393
7-Ethoxycoumarin, improved HPLC assay for assessment of liver slice
metabolic viability, 869
N-Ethylbenzamide, metabolites, detection in urine, NMR spectroscopy
(rats), 1188
5-Ethyl-2 -deoxyuridine
novel (5R,6R)-5-bromo-6-ethoxy-5,6-dihydro prodrugs, pharmacoki-
netics and bioavailability (mice), 223
pharmacokinetics and bioavailability (mice), 223
EXP3174, formation, role of cytochrome P4503A(4), oxidation of losar-
tan, liver microsomes (humans), 285
Eyes
antiglaucoma medication, novel, prostaglandin derivative, ocular ab-
sorption, distribution, and systemic absorption (rabbits), 35
brimonidine, comparative ocular pharmacokinetics after single- dose
application, albino and pigmented rabbits, 708
F(ab)2, immunoglobulin 0, and Fab fragment uptake kinetics, isolated
perfused liver and hepatic cells (rats), 1400
Famciclovir, in vitro conversion to penciclovir, role of aldehyde oxidase,
liver (humans), 251
Fenoprofen, enantiomers, glucuronide conjugates, stereoselective revers-
ible binding properties to human serum albumin, 900
Finasteride, in vitro oxidative metabolism, identification of human cyto-
chrome P450 isozymes responsible for, 1126
FK506, see Tacrolimus
Flavin
adenine dinucleotide-containing and cytochrome P450-dependent mo-
nooxygenases, chiral sulfoxidation of albendazole, liver micro-
somes (rats), 160
-containing monooxygenase, liver, oxidation of aldehydes catalyzed by
(pigs), 1390
-containing monooxygenase 5, selectivity for (S)-sulfoxidation of short-
chain aralkyl sulfides, 1431
-containing monooxygenase-dependent stereoselective N -oxidation,
microsomal, unique pattern, in vitro hepatic metabolism of ABT-
418 (chimpanzees), 1143
Flucytosine, glucuronide conjugate, structural determination (humans),
813
Flurbiprofen, enantiomers, in vitro glucuronidation, characterization, 343
Free radical scavenger, MDL 74,405, disposition and cardioselectivity
after intravenous infusion (rats, dogs), 757
Gabapentin, disposition (mice, rats, dogs, monkeys), 441
Ganciclovir, double prodrug, metabolism and pharmacokinetics (rats,
monkeys), 1242
GBR 12909, oxidation, cytochrome P4502D6-dependent, computer pre-
diction and experimental validation, 667
Gemfibrozil, l-O-13-acyl glucuronide, reactivity, pharmacokinetics of co-
valently bound gemfibrozil-protein adducts (rats), 892
“Gender,” use of term as synonym for sex (letter to the editor), 1007
Glucuronidation, naftazone, liver microsomes (humans, rats), 1305
Glucuronides
acyl glucuronide, gemfibrozil, reactivity (rats), 892
acyl glucuronides, ibuprofen and ibufenac, disposition and reactivity
(monkeys, humans), 566
conjugate of flucytosine, structural determination (humans), 813
conjugates of fenoprofen enantiomers, stereoselective reversible bind-
ing properties to human serum albumin, 900
0-glucuronide, metabolite of LY288513, characterization and plasma
levels (mice, rats, dogs), 910
phenobarbital N-glucuronides, urinary metabolites of phenobarbital
(mice), 548
quaternary ammonium-linked, formation, expressed human UGT1 .4
protein catalyzes, 299
Glutathione
conjugate of clofibric acid, characterization and formation, 119
-dependent metabolism of trichloroethylene, isolated liver and kidney
cells, role in mitochondrial and cellular toxicity (rats), 846
depletion kinetics with acetaminophen, simulation study, 622
formation of conjugates, biotransformation of CI-937, hepatocytes
(rats), 94
verlukast conjugation with, liver and kidney cytosols (rats), 1085
Glyceryl trmnitrate, vasodilation induced by, mechanism of action and
formation of nitric-oxide adduct, 1248
GR117289, microbial biotransformation by Streptomyces rimosus to iden-
tify mammalian metabolite, 724
Haloethene, metabolism, potentiation, role of cytochrome P4502B6, 60
HCFC-124, gas-uptake pharmacokinetics and metabolism (rats, mice,
hamsters), 875
HCFC133a, fluorine-containing metabolites, identification and quantifi-
cation (rats), 102
Hep G2 cells, biosynthesis of S-(2-chloro-l,l,2- trifluoroethyl)glutathione
(rats, humans), 48
Hepatic enzymes, activities, phase I and phase II in vitro, comparison
(humans, dogs, rhesus monkeys, cynomolgus monkeys), 1231
Hepatocytes
biosynthesis of S-(2-chloro-l,l,2-trifluoroethyl)glutathione (rats, hu-
mans), 48
biotransformation of CI-937 (rats), 94
cultured, comparative metabolism of 3 -azido-3 -deoxythymidine (rats,
dogs, monkeys, humans), 308
cultured, regulation of Ah gene battery via Ah receptor-dependent and
independent processes (rats), 642
cultured, sulfation and glucuronidation of acetaminophen (humans),
303data, prediction of in vivo disposition of caffeine, 349
N-(3,5-dichlorophenyl)succinimide metabolism (rats), 107
isolated, and precision-cut liver slices, quantitative differences in phase
I and II metabolism (rats), 1274
mofarotene metabolism, different species, comparison with in vivo data
and evaluation of cytochrome P450 isoenzymes involved in human
biotransformation, 1051
primary culture, cytochrome P450 activities, effect of model inducers
(humans), 553
primary cultured, xenobiotic-enhanced expression of cytochrome P450
2E1 and 2Bl/2B2 (rats), 681
primary cultures, cytochrome P4503A induction, comparative analysis
(rats, rabbits, humans), 415
1444 SUBJECT INDEX
acetyl coenzyme A:arylamine N-acetyltransferase activity (rats), 295
contribution to presystemic elimination of morphine (rabbits), 584 acetyl coenzyrne A:arylamine N-acetyltransferase activity (rats), 295
primary cultures, cytochrome P4503A induction and inhibition by
tiamulin (pigs), 542
Hexachlorobutadiene metabolite, N-acetyl-S-(pentachlorobutadienyl)- L-
cysteine, sex-specific sulfoxidation, role ofcytochrome P4503A1/2
(rats), 861
HFA134a, inhaled, disposition, healthy subjects and patients with chronic
airflow limitation, 832
HIV- 1 protease inhibitors
L-689,502, metabolism, liver slices (rats), 185
L-735,524, metabolites, urine (humans), 266
L-735,524, pH-dependent oral absorption (rats, dogs), 730
SK&F 107461, metabolites, characterization using liquid chromatogra-
phy/mass spectrometry (rats), 799
HIV-l reverse Iranscriptase inhibitor, L-738,372, metabolism, species
differences, in vitro and in vivo studies (rats, dogs, monkeys,
humans), 688
HPLC assay, improved, for assessment of liver slice metabolic viability
using 7-ethoxycoumarmn, 869
5-HI3 receptor antagonist, dolasetron mesylate, metabolism (humans),
806
Hydralazine, mutagenicity, role of acetylation, 559
Hydroxylamine, formation and reduction, role of cytochrome P4502C
subfamily, hepatic microsomes (rats, humans), 406
3-Hydroxypyridin-4-one chelating agents
metabolism and urinary recovery, effect of iron overload (rats), 314
orally active, bioavailability and disposition, influence of lipophilicity,
1178
Hypochlorous acid, oxidation of 5-aminosalicylic acid to reactive imino-
quinone, possible role in treatment of inflammatory bowel dis-
eases, 246
Ibufenac, acyl glucuronides, disposition and reactivity, comparison with
ibuprofen (monkeys, humans), 566
Ibuprofen, acyl glucuronides, disposition and reactivity, comparison with
ibufenac (monkeys, humans), 566
Ifosfamide, administration, formation of chloroethylamine and 1 ,3- ox-
azolidine-2-one (humans), 433
Iloperidone, in vitro and in vivo metabolites, rapid identification, appli-
cation of hyphenated LCINMR and LCIMS techniques, 951
Imidazole, expression of microsomal epoxide hydrolase gene (rats), 460
Imidocarb, residues in edible bovine tissues and in vitro assessment of
metabolism and cytotoxicity, 501
Iminium ion, mechanism-based inactivation of liver cytochrome P4502B 1
(rats), 786
Iminoquinone, reactive, oxidation of 5-aminosalicylic acid, possible role
in treatment of inflammatory bowel diseases, 246
Imipramine, repetitive administration, inhibition and induction of cyto-
chrome P450 isozymes (rats), 999
Immunoglobulin 0, F(ab )2’ and Fab fragment uptake kinetics, isolated
perfused liver and hepatic cells (rats), 1400
Immunosuppressants, see Tacrolimus
Indole-3-carbinol, mechanisms of tumor modulation, disposition and ex-
cretion (rats), 965
Infection, -mediated suppression of oxidative hepatic drug metabolism
and cytochrome mRNA levels (pigs), 44
Inflammatory bowel diseases, treatment, possible role of oxidation of
5-aminosalicylic acid to reactive iminoquinone, 246
Interferon inducer, polyinosinic acid-polycytidylic acid, downregulation
of cytochrome P450, influence of duration of induction and spe-
cies, 536
Interleukin-2, recombinant human, comparison of mass balance, pharma-
cokinetics, and disposition (monkeys), 904
Intestine
cultured epithelial cell monolayers, transport and metabolism of delta
sleep-inducing peptide (humans), 1372
sites of biotransformation for SDZ 1MM 25 (humans), 327
Intestine, small, see Small intestine
Iron, overload, effect on metabolism and urinary recovery of 3- hydroxy-
pyridin-4-one chelating agents (rats), 314
Isoflurane, interaction with chlorodifluoroethene, liver microsomes, role
of cytochrome P4502B6 in potentiation of haloethene metabolism
(humans), 60
Jacobine, susceptibility of guinea pig to, major factors for, 1263
Ketoprofen, -treated adjuvant arthritis, severity of inflammation, influence
on disposition kinetics of propranolol enantiomers, 240
Kidney
acetyl coenzyme A:arylamine N-acetyltransferase activity (rats), 295
benzoic acid glycine conjugation (rats), 255
bioactivation of acetaminophen, in vitro, contribution of oxidation and
deacetylation (rats), 290
catabolism of recombinant human soluble CD4, after intravenous ad-
ministration (rats), 1044
CYP1A1 and CYPIA2 expression, 3-methylcholanthrene and pyridine
effects (rats), 818
cytosols, verlukast conjugation with glutathione (rats), 1085
importance of, disposition of morphine-3-glucuronide, intravenous in-
fusions (sheep), 334
isolated cells, glutathione-dependent metabolism of trichloroethylene,
role in mitochondrial and cellular toxicity (rats), 846
nephrotoxicity, 2,3,5-(triglutathion-S-yl)hydroquinone-mediated, spe-
cies susceptibility to, metabolism as determinant, role of N- acety-
lation and N-deacetylation, 1 136
sites of biotransformation for SDZ 1MM 25 (humans), 327
L-689,502, metabolism, liver slices (rats), 185
L-702,539, in vivo and in vitro biotransformations, 65
L-708,404, disposition (rats, monkeys, chimpanzees), 1 104
L-735,524
metabolites, urine (humans), 266
pH-dependent oral absorption (rats, dogs), 730
L-738,372, metabolism, species differences, in vitro and in vivo studies
(rats, dogs, monkeys, humans), 688
L-739,010, microsomal metabolism to reactive intermediates that co-
valently bind to protein, role of 6,8-dioxabicyclo[3.2.l]octanyl
moiety, 1325
L-746,530, microsomal metabolism to reactive intermediates that co-
valently bind to protein, role of 6,8-dioxabicyclo[3.2.l]octanyl
moiety, 1325
Lansoprazole, and omeprazole, comparative pharmacokinetic/pharmaco-
dynamic study (rats), 718
Lauric acid hydroxylase activities, liver (humans), 1037
LC/NMR and LCIMS techniques, application, rapid identification of in
vitro and in vivo metabolites of iloperidone, 951
Lidocaine
as inhibitor of liver CYP1A1 activity, relative potency (rats), 1335
metabolism, lack of residual effects of diethyl ether, methoxyflurane,
and sodium pentobarbital, single-pass isolated liver perfusion sys-
tern (rats), 525
Lipophilicity, influence on bioavailability and disposition of orally active
3-hydroxypyridin-4-one metal chelators, 1178
Lipoxygenase inhibitors, microsornal metabolism to reactive interrnedi-
ates that covalently bind to protein, role of 6,8-dioxabi-
cyclo[3.2.l]octanyl moiety, 1325
Liver
SUBJECT INDEX 1445
bioactivation of acetaminophen, in vitro, contribution of oxidation and
deacetylation (rats), 290
chiral sulfoxidation of albendazole (rats), 160
contribution to presystemic elimination of morphine (rabbits), 584
conversion of famciclovir to penciclovir, role of aldehyde oxidase
(humans), 251
cytochrome P4503A induction and inhibition by tiamulin (pigs), 542
cytosols, verlukast conjugation with glutathione (rats), 1085
disposition of ciprofloxacin (rats), 197
flavin-containing monooxygenase, oxidation of aldehydes catalyzed by
(pigs), 1390
intoxication by carbon tetrachloride, effect on hepatic local disposition
of oxacillin, 779
isolated cells, glutathione-dependent metabolism of trichloroethylene,
role in mitochondrial and cellular toxicity (rats), 846
kinetics of drug metabolism, examples of high- and low-clearance
compounds (rats), 393
lauric acid hydroxylase activities (humans), 1037
metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid
(rats), 363
metabolism of ABT-41 8, pattern of microsomal flavin-containing mo-
nooxygenase-dependent stereoselective N -oxidation (chimpan-
zees), 1143
metabolism of budesonide by cytochrome P450 3A enzymes (humans),
137
metabolism of [‘4C]naphthalene, 129
metabolism of propranolol, fetal (sheep), 190
metabolism studies, microdialysis sampling, impact on liver tissue,
1072
oxidation of tolualdehydes to toluic acids, catalyzed by cytochrome
P450-dependent aldehyde oxygenase (mice), 261
oxygenation, effects of chronic left ventricular failure (rats), 485
sites of biotransformation for SDZ 1MM 25 (humans), 327
slices, precision-cut, and isolated hepatocytes, quantitative differences
in phase I and II metabolism (rats), 1274
volume, as determinant of drug clearance, children and adolescents,
1110
Liver microsomes
carboxylesterase levels, interindividual variation (humans), 1022
cytochrome P450 inhibitors, in vitro metabolism of therapeutic agents,
evaluation of specificities (humans), 154
induction of cytochrome P450 (monkeys), 736
isoflurane-chlorodifluoroethene interaction, role of cytochrome
P4502B6 in potentiation of haloethene metabolism (humans), 60
metabolism of O-benzylguanine (rats), 1394
mofarotene metabolism, different species, comparison with in vivo data
and evaluation of cytochrome P450 isoenzymes involved in human
biotransformation, 1051
oxidation of losartan, role of cytochrome P4503A(4) in formation of
EXP3174 (humans), 285
reduction and glucuronidation of naftazone (humans, rats), 1305
rifampicin-treated, cytochrome P450 metabolic-intermediate complexformation from nonmacrolide amines, enhanced rates (rabbits),
1379
stereoselective glucuronidation of zileuton isomers (humans), 149
verapamil-infused isolated, input rate-dependent stereoselective phar-
macokinetics (rats), 637
WR 238605 metabolism (rats), 1
Loperamide
gastrointestinal distribution (dogs), 216
reduction of loperamide oxide, gut (rats, dogs, humans), 354
Loperamide oxide
gastrointestinal distribution (dogs), 216
reduction to loperamide, gut (rats, dogs, humans), 354
Losartan
biotransformation to active carboxylic acid metabolite, liver micro-
somes (humans), 207
oxidation, role of cytochrome P450 3A(4) in formation of EXP3 174,
liver microsomes (humans), 285
Losoxantrone, two regioisomeric monocarboxylic acid metabolites ex-
creted in urine (humans), 600
Lungs
cells, oxidation at C-l, control of l,1-dichloro-2,2-bis(p- chlorophe-
nyl)ethane cytotoxicity (rabbits, humans), 595
contribution to presystemic elimination of morphine (rabbits), 584
LY255582, disposition (rats, dogs), 916
LY2885 13, 0-glucuronide metabolite, characterization and plasma levels
(mice, rats, dogs), 910
Mafosfamide, human breast adenocarcinoma MCF-7/0 cells electropo-
rated with cytosolic class 3 aldehyde dehydrogenases obtained
from tumor cells and normal tissue, differential sensitivity, 1080
cis-Malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]-
platinum(II), pharmacokinetics, tissue distribution, and excretion
(dogs), 1280
MDL 74,405, disposition and cardioselectivity after intravenous infusion
(rats, dogs), 757
Meloxicam, pharmacokinetics and metabolic pattern, after intravenous
infusion and oral administration, healthy subjects, 1206
Metabolic-intermediate complex, formation from nonmacrolide amines,
cytochrome P450, enhanced rates, rifampicin-treated liver micro-
somes (rabbits), 1379
Metabolite-intermediate complex, formation, evidence, effect of cimeti-
dine on hepatic cytochrome P450, 1407
Methamphetamine, enantiomers, 4-hydroxylation, catalysis by cyto-
chrome P4502D isozymes, 610
Methemoglobin, formation by antimalarial drugs, improved pharmacody-
namic model, 573
Methionine, infusion, in vivo modification of 3 -phosphoadenosine 5
-phosphosulfate and sulfate, 840
Methoxyflurane, lack of residual effects on lidocaine metabolism, single-
pass isolated liver perfusion system (rats), 525
3-Methylcholanthrene, effects on CYP1A1 and CYPIA2 expression, renal
tissue (rats), 818
S-Methyl N,N-diethylthiolcarbamate, sulfoxidation, identification of P450
enzymes responsible for (humans, rats), 1 153
Metoprolol, regioselective and stereoselective oxidation, catalyzed by
microsomes containing cDNA-expressed P4502D6 (humans), 513
Mexiletine, as inhibitor of liver CYP1A1 activity, relative potency (rats),
1335
Microdialysis sampling, hepatic metabolism studies, probe design and
implantation technique, impact on liver tissue, 1072
MK-0679, see Verlukast
Mofarotene, metabolism in hepatocytes and liver microsomes, different
species, comparison with in vivo data and evaluation of cyto-
chrome P450 isoenzymes involved in human biotransformation,
1051[‘4CjMonocrotaline, pyrrolic metabolites, biliary excretion (rats), 422
Monooxygenase
activities, brain cytochrome P450, reassessment (rats), 651
-dependent stereoselective N -oxidation, microsomal flavin- containing,
unique pattern, in vitro hepatic metabolism of ABT-418 (chimpan-
zees), 1143
flavin adenine dinucleotide-containing and cytochrome P450- depen-
dent, chiral sulfoxidation of albendazole, liver microsomes (rats),
160
flavin-containing, liver, oxidation of aldehydes catalyzed by (pigs),
1390
Monooxygenase 5, flavin-containing, selectivity for (S)- sulfoxidation of
1446 SUBJECT INDEX
short-chain aralkyl sulfides, 1431
Morphine
comparative disposition during separate intravenous infusions of mor-
phine and morphine-3-glucuronide, importance of kidney (sheep),
334
presystemic elimination, contribution of intestine, liver, and lungs (rab-
bits), 584
Morphine-3-glucuronide
biliary excretion and enterohepatic recirculation (rats), 478
comparative disposition during separate intravenous infusions of mor-
phine and morphine-3-glucuronide, importance of kidney (sheep),
334
3-Morpholinosydnonimine, vasodilation induced by, nitric oxide forma-
tion concurrent with, time-dependent increase, 1248
NADPH-P450
oxidoreductase, dependency on, cDNA-directed expression of cyto-
chrome P450 lAl using baculovirus (humans), 696
reductase, purified recombinant fusion protein containing, in vitro me-
tabolism of terfenadine, 765
Naftazone, reduction and glucuronidation, liver microsomes (humans,
rats), 1305
[‘4C]Naphthalene, metabolism in B6C3F, murine isolated perfused liver,
129
Naphthalenic lignan lactone 5-lipoxygenase inhibitor, L-702,539, in vivo
and in vitro biotransformations, 65
j3-Naphthoflavone, rats pretreated with, acitretin elimination, 465
Naproxen glucuronide, stereoselective disposition (rats), 1099
Nephrotoxicant, N-(3,5-dichlorophenyl)succinimide, metabolism, isolated
hepatocytes (rats), 107
Neurontin, disposition (mice, rats, dogs, monkeys), 441
Nicotine
accumulation, pigmented and unpigmented hair (rats), 143
metabolites, in brain, after peripheral radiolabeled nicotine administra-
tion, detection of nornicotine (rats), 1175
(S)-Nicotine, cytochrome P450-catalyzed oxidation, stereoselectivity and
isotope effects, 749
S-Nitroso-N-acetylpenicillamine, vasodilation induced by, nitric oxide
formation concurrent with, time-dependent increase, 1248
NMR spectroscopy, detection of metabolites of N-ethylbenzamide and
N,N-diethylbenzamide, urine (rats), 1188
Nonmacrolide amines, cytochrome P450 metabolic-intermediate complex
formation, enhanced rates, rifampicin-treated liver microsomes
(rabbits), 1379
Nornicotine, detection of, after peripheral radiolabeled nicotine adminis-
tration (rats), 1175
1-O-Octadecyl-2-O-methyl-rac-glycero-3-phosphocoline, see ET18-OMe
Omeprazole, and lansoprazole, comparative pharmacokinetic/pharmaco-
dynamic study (rats), 718
Ondansetron, metabolism, multiple forms of cytochrome P450 involved in
(humans), 1225
Opioid antagonist, LY255582, disposition (rats, dogs), 916
Oxacillin, hepatic local disposition, effect of liver intoxication by carbon
tetrachloride, 779
Oxazepam, metabolism and elimination (F344 rats), 232
1,3-Oxazolidine-2-one, formation following ifosfamide administration
(humans), 433
Oxandrolone, induction of “male-specific” cytochrome P450 isozymes
(female rats), 1291
Oxidation, use of “oxygenation” as synonym for (letter to the editor), 1007
N -Oxidation, stereoselective, microsomal flavin-containing monooxyge-
nase-dependent, unique pattern, metabolism of ABT-418 (chim-
panzees), 1143
Oxidative hepatic drug metabolism, infection-mediated suppression
(pigs), 44
“Oxygenation,” use of term as synonym for oxidation (letter to the editor),
1007
Pacitaxel, see Taxol
Paraoxonases, purified serum, comparison (humans, rabbits), 935
Penciclovir, in vitro conversion of famciclovir to, role of aldehyde oxi-
dase, liver (humans), 251
Perillyl alcohol, oral administration, pharmacokinetics of active drug
metabolites (dogs), 676
Peritoneal membrane transport, acidic drugs, physiological pharmacoki-
netic concepts, 1220
Peroxisomal a-oxidation, and metabolic pathway of (+)-S-l45, 1195
Pharmacogenetics, thiopurine methyltransferase, cloning of human liver
cDNA and processed pseudogene on human chromosome 18q21 . I,
398
Pharmacokinetics, species similarities and differences, 1008
Phencyclidine
inactivation of constitutive hepatic cytochromes P450 (rats), 201
mechanism-based inactivation of liver cytochrome P4502B1 (rats), 786
Phenobarbital
-inducible dog liver cytochrome P450, major, benzyloxyresorufin as
specific substrate for, 1434
pretreatment with, acitretin elimination (rats), 465
urinary metabolites, phenobarbital N-glucuronides (mice), 548
Phenobarbital N-glucuronides, urinary metabolites of phenobarbital
(mice), 548
Phenol sulfotransferase, monoamine-sulfating form, bacterial expression
and kinetic characterization (humans), 945
3 -Phosphoadenosine 5 -phosphosulfate, in vivo modification by infusion
of sodium sulfate, cysteine, and methionine, 840
Phosphodiester bond, rapid plasma clearance and metabolism in vitro of
phosphorothioate oligodeoxynucleotide, 1297
Phosphodiester oligodeoxynucleotide, pharmacokinetics and organ clear-
ance, 55
Phosphorothioate oligodeoxynucleotide, rapid plasma clearance and me-tabolism in vitro with phosphodiester bond, 1297
Polyinosinic acid-polycytidylic acid, downregulation of cytochrome P450,
influence of duration of induction and species, 536
Primaquine, metabolism, side-chain hydroxylation, 18
Progesterone
21-hydroxylase activity, cytochrome P450 PBD-21P450 2B 1 1, charac-
terization through reconstitution, heterologous expression, and site-
directed mutagenesis (dogs), 702
induction of catechol-O-methyltransferase in luminal epithelium of
uterus, inhibition by RU-486 (rats), 430
Propranolol
enantiomers, disposition kinetics in ketoprofen-treated and untreated
adjuvant arthritis, influence of severity of inflammation, 240
first-pass uptake and systemic clearance, contribution of small intestine
(rabbits), 279
fetal hepatic metabolism (sheep), 190
interaction with amino acids, single-pass isolated, perfused liver (rats),
794
Prostaglandin derivative, ocular absorption, distribution, and systemic
absorption (rabbits), 35
Proton pump inhibitors, omeprazole and lansoprazole, comparative phar-
macokinetic/pharmacodynamic study (rats), 718
Pyridine
effects on CYP1A1 and CYP1A2 expression, renal tissue (rats), 818
enhanced expression of cytochrome P450 2E1 and 2B1/2B2, primary
cultured hepatocytes (rats), 681
inhalation exposure, induction of nasal carboxylesterase (rats), 529
SUBJECT INDEX 1447
travenous injection (rats), 1368
Pyrrolizidine alkaloids, jacobine, susceptibility of guinea pig to, major
factors, 1263
Radioassay combined with autoradiography, utility, tissue distribution
studies and cytopharmacology, 885
Recombinant human interleukin-2, comparison of mass balance, pharma-
cokinetics, and disposition (monkeys), 904
Recombinant human soluble CD4, renal catabolism after intravenous
administration (rats), 1044
4-5a-Reductase, in vitro metabolism of tirilazad mesylate (rats), 383
Respiratory syncytial virus-specific reshaped monoclonal antibody
RSHZ19, preclinical pharmacokinetic evaluation, 1028
Retinoic acid
all-trans-
isomerization and metabolism, and dysmorphogenic effects on em-
bryos during neurulation, 1058
time- and dose-dependent kinetics, oral or intravenous administration
(rats), 227
9-cis-
isomerization and metabolism, and dysmorphogenic effects on em-
bryos during neurulation, 1058
oral, metabolism, identification of 9-cis-retinoyl-f3- glucuronide and
9-cis-4-oxo-retinoy1-�3-glucurothde as urinary metabolites (hu-
mans), 887
Retinoid metabolism, embryonic, model system for study of, Xenopus
laevis
isomerization and metabolism of all-trans-retinoic acid and 9- cis reti-
noic acid, and dysmorphogenic effects on embryos during neuru-
lation, 1058
metabolism of 9-cis- and all-trans-retinals and retinols to their cone-
sponding acid forms, 72
metabolism of aJl-trans-3,4-didehydroretinol to all-trans-3,4- didehy-
droretinoic acid, 83
Rifampicin, -treated liver microsomes, cytochrome P450 metabolic- in-
termediate complex formation from nonmacrolide amines, en-
hanced rates (rabbits), 1379
RU-486, inhibition of induction of catechol-O-methyltransferase in lumi-
nal epithelium of uterus by progesterone (rats), 430
(+)-S-l45, metabolic pathway, in vitro studies, evidence for two meta-
bolic pathways in peroxisomal /3-oxidation (rats), 1195
Scientific writing, use of “causalisms” (letter to the editor), 1 107
SDZ 1MM 125
liver cytochrome P4503A biotransformation (humans), 321
sites for biotransformation, liver and kidney slices and intestine (hu-
mans), comparison with rat liver slices and cyclosporin A metab-
olism, 327
Sequential metabolism, kinetics, 166
Sevoflurane, biotransformation, neonate liver slices (rat), 497
Sex, use of “gender” as synonym for (letter to the editor), 1007
Short-chain aralkyl sulfides, (S)-sulfoxidation, selectivity of flavin-con-
mining monooxygenase 5, 1431
Sigma receptor antagonist, novel, DuP 734, pharmacokinetics and presys-
temic first-pass elimination (rats), 603
SK&F 107461, metabolites, characterization using liquid chromatogra-
phy/mass spectrometry (rats), 799
Small intestine
metabolism of tacrolimus, cytochrome P450, drug interactions, and
interindividual variability, 1315
mucosa, metabolism of [‘4C]l,3-dinitrobenzene in vitro
(rats), 982
role in first-pass uptake and systemic clearance of propranolol (rabbits),
279
Sodium mercaptoundecahydrododecaborate, pharmacokinetics, after in-
Sodium nitroprusside, vasodilation induced by, nitric oxide formation
concurrent with, time-dependent increase, 1248
Sodium pentobarbital, lack of residual effects on lidocaine metabolism,
single-pass isolated liver perfusion system (rats), 525
Sodium sulfate, infusion, in vivo modification of 3 - phosphoadenosine 5
-phosphosulfate and sulfate, 840
Spectroscopy, NMR, detection of metabolites of N-ethylbenzamide and
N,N-diethylbenzamide, urine (rats), 1188
Streptomyces rimosus, microbial biotransformation of GR1 17289 to iden-
tify mammalian metabolite, 724
Streptozotocin, -induced diabetes, effects on liver sulfotransferase gene
expression (rats), 455
Sulfamethoxazole, N4-hydroxylation by cytochrome P450, hepatic micro-
somes (rats, humans), 406
Sulfate, in vivo modification by infusion of sodium sulfate, cysteine, and
methionine, 840
Sulfinpyrazone, and metabolites, inhibition of (S)-warfarin metabolism,
659
Sulfotransferase, liver gene expression, effects of streptozotocin- induced
diabetes (rats), 406
(S)-Sulfoxidation, short-chain aralkyl sulfides, selectivity of flavin-con-taming monooxygenase 5, 1431
Sustained-release preparation, in vivo drug release rate constant, method
of determining, 449
Tacrine, use as isoenzyme-specific probe, determination of hepatic cyto-
chrome P4501A2 activity (humans), 929
Tacrolimus (FK506)
metabolism, identification and biological activities of metabolites oxi-
dized at multiple sites, 28
metabolism, small intestine, cytochrome P450, drug interactions, and
interindividual variability, 1315
Tamoxifen
acidic metabolites, aspects of formation and fate (female rats), 993
metabolites, identification in human HEP 02 cell line, human liver
homogenate, and patients on long-term therapy for breast cancer,
377
Taxol
metabolism, dexamethasone induction of (rats), 1286
metabolism and disposition, cancer patients, 506
plasma and tissue disposition after intraperitoneal administration
(mice), 713
Terfenadine
in vitro metabolism by purified recombinant fusion protein containing
cytochrome P4503A4 and NADPH-P450 reductase, 765
metabolism associated with CYP3A(4) activity, hepatic microsomes
(humans), 631
1,l,l,2-Tetrafluoroethane, inhaled, disposition, healthy subjects and pa-
tients with chronic airflow limitation, 832
Tetrahydrocannabinol, metabolites, brain kinetics, effect of cannabidiol
pretreatment (mice), 825
Theophylline, elimination, effects of chronic left ventricular failure (rats),
485Thienodiazepine platelet-activating factor receptor antagonist, interspe-
cies scaling, 776
Thiopurine methyltransferase, pharmacogenetics, cloning of human liver
cDNA and processed pseudogene on human chromosome 1 8q2l .1,
398
Thromboxane A2 receptor antagonist, (+)-S-l45, metabolic pathway, in
vitro studies, evidence for two independent pathways in peroxiso-
mal a-oxidation, 1195
Tiamulin, induction and inhibition of cytochrome P450 3A, studies in
primary hepatocyte cultures and liver microsomes (pigs), 542
Tirilazad mesylate, in vitro metabolism, contribution of cytochrome
P4502C1 1 and 4-5o-reductase (rats), 383
1448 SUBJECT INDEX
Tissue distribution studies
relevance (letter to the editor), 159
relevance, utility of radioassay combined with autoradiography, 885
Tocainide, as inhibitor of liver CYP1A1 activity, relative potency (rats),
1335
Tolbutamide, rates of oxidation, liver slices (rats), 393
Tolmetin glucuronide, reactivity with human serum albumin, identifica-
tion of binding sites and mechanisms of reaction, 369
Tolualdehydes, oxidation to toluic acids, catalysis by cytochrome P450-
dependent aldehyde oxygenase, liver (mice), 261
Toluic acids, oxidation of tolualdehydes to, catalysis by cytochrome
P450-dependent aldehyde oxygenase, liver (mice), 261
Topiramate, pharmacokinetics and bioavailability (dogs), 90
Trichioroethylene, glutathione-dependent metabolism, isolated liver and
kidney cells, role in mitochondrial and cellular toxicity (rats), 846
Trifluoroacetic acid, trace, utility to enhance quality of proton NMR
spectra of xenobiotic metabolites, 1004
2,3,5-(Triglutathion-S-yl)hydroquinone, -mediated nephrotoxicity, spe-
cies susceptibility to, metabolism as determinant, role of N- acety-
lation and N-deacetylation, 1136
Tumor cells, cytosolic class 3 aldehyde dehydrogenases obtained from,
human breast adenocarcinoma MCF-7/0 cells electroporated with,
sensitivity to mafosfamide, 1080
UGT1 .4 protein, expressed human, catalyzes formation of quaternary
ammonium-linked glucuronides, 299
Urine
chromium screening (letters to the editor), 607
excretion of cicletanine, stereochemical aspects (rats), 988
metabolites of N,N-diethylbenzamide, detection by NMR spectroscopy
(rats), 1188
metabolites of N-ethylbenzamide, detection by NMR spectroscopy
(rats), 1188
metabolites of L-735,524 (humans), 266
metabolites of oral 9-cis-retinoic acid, identification (humans), 887
metabolites of phenobarbital, phenobarbital N-glucuronides (mice), 548
recovery of 3-hydroxypyridin-4-one chelating agents, effect of iron
overload (rats), 314
Uterus, luminal epithelium, induction of catechol-O- methyltransferase by
progesterone, inhibition by RU-486 (rats), 430
Valproic acid, pharmacokinetics, pregnant sheep, after maternal and fetal
intravenous bolus administration, 1383Verapamil, -infused isolated livers, input rate-dependent stereoselective
pharmacokinetics, 637 (rats), 637
Verlukast (MK-0679), conjugation with glutathione, liver and kidney
cytosols and excretion in bile (rats), 1085
Vitamin E analog, MDL 74,405, disposition and cardioselectivity after
intravenous infusion (rats, dogs), 757
R-Warfarin, metabolism, as probe, cytochromes P450 1A1 and P450 1A2
(humans), 1339
(S)-Warfarin, metabolism, inhibition by sulfinpyrazone and metabolites,
659
WR 1995, metabolism, side-chain hydroxylation, 18
WR 238605, metabolism, liver microsomes (rats), 1
WR 6026, metabolism, side-chain hydroxylation, 18
Xenobiotics
biotransformation, minimal effects of aldose reductase inhibitors, sub-
acute topical-ocular dosing (rabbits), 1094
enhanced expression of cytochrome P450 2E1 and 2Bl/2B2, primary
cultured hepatocytes (rats), 681
metabolites, proton NMR spectra, quality enhancement, utility of trace
trifluoroacetic acid, 1004
Xenopus laevis, model system for study of embryonic retinoid metabolism
embryonic metabolism of a11-trans-3,4-didehydroretinol to all- trans-
3,4-didehydroretinoic acid, 83
embryonic metabolism of 9-cis- and all-trans-retinals and retinols to
their corresponding acid forms, 72
isomerization and metabolism of all-trans-retinoic acid and 9- cis reti-
noic acid, and dysmorphogenic effects on embryos during neuru-
lation, 1058
YM175, pharmacokinetics, (rats, dogs), 1214
Zileuton
isomers, stereoselective glucuronidation, hepatic microsomes (humans),
149
metabolism, liver cytochrome P450 enzymes involved in, identification
of(humans), 1163
Zolpidem, oxidative metabolism by human liver cytochrome P450s, 1253
Copyright © 1995 by The American Society for Pharmacology
and Experimental Therapeutics
��‘�-a
1�
r. ‘r I
h��HE JOURNALOF�‘� � J�PEFisrespect�ewor1doveras
DUADUA(AIN�V , oneo’�’� azthjouriiaI�F I1I4RIUI4WLW 1 j�-� thE �co1ogy. Readers
AND EXPERIMENTAL aspects of
ThERAPEUTICS
The Journal of Pharmacology and
Experimental Therapeutics (monthly)
� Individual 5190/ year
E Institutional $370/year
(Add $75/yr. for ��Stg outside’ the U.S.:
in Canada, also add 7 ‘ GST)
� New Subscription � Renewal
E 3 years E 2 years E 1 year
PAYMENT OPTIONS:
E Check enclosed (payable to Williams & Wilkins)
Li Bill me � Am Ex � MC fl VISA
I’�
rI,
II
pharmacologists as well as toxicolo-
gists. Thejoumal deserves a place
in every phaimaceulica1a�
logical reseaithIabor�
ma�
PT 555)5 Printed in LSA
‘1
T�
LoniSeJ044Z
5-2357, �.
�
t
Editor: John Harvey, PhD,
The Medical College of Pennsylvania
k
� � Yes! Please start my subscription. I
. Avoid future rate increases and ensure Iuninterrupted service -enter your I
I multiyear subscription today!
I I
/1
CardS Exp. date
Signature I P.O.#
Address
City I State! Zip!Country
MD,ME,and IL subscribers mustadd state salestax. Subscriptions outsidethe U S. must be prepaid in U.S dollars only In Japan, contact Igaku-ShoinMYW Ltd (03) 5689-5400. Rates valid through October 31 . 1996
Discounts available to members on all ASPET publications. SAVE 10%when ordering two SAVE 15% when ordering three SAVE 20’/� whenordering all four
:“� Return coupon to: Williams & Wilkins, A Waverly Company,
P.O. Boo 23291, Baltimore, MD 21203-9990.
biological systems, inc1udi�:�
� autonomic pharmacc.�
� analgesia
� behavioral pharmacology .-. -�
� cardiovasculijh�n�acology
,� cellular phartM�o1�� �
,‘ chemotherapy �:
��. �id���mr �naco1ogy
�‘ druga�bse ‘�‘-� - -
� dnig metabolism & di� lion
� gastrointestinal p� � - V
� immunopharmaco1�� ,. �----�------ -
�
�, rena�& i..f. --�. toxicology�
��1PET is valuable n�adingfor ‘�
academic, industrial and dinical
rbycr
L-FREE 1-800-63�
America. Outsi
�: 1-410-36
o� intemat
